How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

Findings showed 60 percent reduction in risk of disease progression or death with daratumumab SC quadruplet regimen compared to current standard of care triplet regimen 1 “Optimising frontline therapy ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...

Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable. There is a commercial ...

I know there is a online library where one can search for any medicine and look up the associated package insert for dosage and instructions. Do you know the online address by any change. Wonderful to ...

A second study will evaluate the treatment and financial burden and quality of life of a program of subcutaneous daratumumab administered at home. When multiple therapeutic combinations are listed ...